Investing in Alliance Pharmaceuticals

At a glance

Our 2021 Financial Highlights

Strong overall revenue growth driven by Consumer Healthcare, underpinned by continued market penetration via e-commerce activity, which now represents around 25% of Group sales

169.6 £m See-through Revenue*

42.2 £m Underlying Profit Before Tax

6.39p Underlying Basic EPS

163.2 £m Statutory Revenue

18.2 £m Reported Profit Before Tax

*Non-IFRS alternative performance measures. See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.

Results centre

2021 Annual Report

Annual Report

2021 Annual Report (7.6mb)

Built for modern business

An inter-connected network of people and brands

A global range of products delivering outstanding value. Many partners working together; one team, achieving more.

A global business

Headquartered in the UK, with affiliated offices in Europe, the Far East and the US

• Wide international reach through an extensive network of distributors
• Sales in more than 100 countries

Our global locations

Our business model

Our business model sets out how we execute our strategy to deliver on our purpose: making a difference to people’s lives, through making a range of clinically valuable healthcare products available to consumers and patients around the world.

Our business model

Our portfolio

Alliance Pharma holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold worldwide in more than 100 countries.

Our brands